Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 114

Similar articles for PubMed (Select 24084072)

1.

Predictors of response to tiotropium versus salmeterol in asthmatic adults.

Peters SP, Bleecker ER, Kunselman SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT, Boushey HA, Calhoun WJ, Castro M, Cherniack RM, Craig T, Denlinger LC, Engle LL, Dimango EA, Israel E, Kraft M, Lazarus SC, Lemanske RF Jr, Lugogo N, Martin RJ, Meyers DA, Ramsdell J, Sorkness CA, Sutherland ER, Wasserman SI, Walter MJ, Wechsler ME, Chinchilli VM, Szefler SJ; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network.

J Allergy Clin Immunol. 2013 Nov;132(5):1068-1074.e1. doi: 10.1016/j.jaci.2013.08.003. Epub 2013 Sep 29.

2.

Tiotropium bromide step-up therapy for adults with uncontrolled asthma.

Peters SP, Kunselman SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT, Boushey HA, Calhoun WJ, Castro M, Cherniack RM, Craig T, Denlinger L, Engle LL, DiMango EA, Fahy JV, Israel E, Jarjour N, Kazani SD, Kraft M, Lazarus SC, Lemanske RF Jr, Lugogo N, Martin RJ, Meyers DA, Ramsdell J, Sorkness CA, Sutherland ER, Szefler SJ, Wasserman SI, Walter MJ, Wechsler ME, Chinchilli VM, Bleecker ER; National Heart, Lung, and Blood Institute Asthma Clinical Research Network.

N Engl J Med. 2010 Oct 28;363(18):1715-26. doi: 10.1056/NEJMoa1008770. Epub 2010 Sep 19.

3.

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma.

Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, Fabbri LM.

J Allergy Clin Immunol. 2011 Aug;128(2):315-22. doi: 10.1016/j.jaci.2011.06.004.

PMID:
21807250
4.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
5.

Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients.

Beier J, van Noord J, Deans A, Brooks J, Maden C, Baggen S, Mehta R, Cahn A.

Int J Chron Obstruct Pulmon Dis. 2012;7:153-64. doi: 10.2147/COPD.S26100. Epub 2012 Mar 5.

6.

Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.

Wechsler ME, Kunselman SJ, Chinchilli VM, Bleecker E, Boushey HA, Calhoun WJ, Ameredes BT, Castro M, Craig TJ, Denlinger L, Fahy JV, Jarjour N, Kazani S, Kim S, Kraft M, Lazarus SC, Lemanske RF Jr, Markezich A, Martin RJ, Permaul P, Peters SP, Ramsdell J, Sorkness CA, Sutherland ER, Szefler SJ, Walter MJ, Wasserman SI, Israel E; National Heart, Lung and Blood Institute's Asthma Clinical Research Network.

Lancet. 2009 Nov 21;374(9703):1754-64. doi: 10.1016/S0140-6736(09)61492-6.

7.

Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.

Chong J, Karner C, Poole P.

Cochrane Database Syst Rev. 2012 Sep 12;9:CD009157. doi: 10.1002/14651858.CD009157.pub2. Review.

PMID:
22972134
8.

Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.

Bateman ED, van Dyk M, Sagriotis A.

Pulm Pharmacol Ther. 2008;21(1):20-5. Epub 2006 Oct 13.

PMID:
17118684
9.

Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews.

Cates CJ, Wieland LS, Oleszczuk M, Kew KM.

Cochrane Database Syst Rev. 2014 Feb 6;2:CD010314. doi: 10.1002/14651858.CD010314.pub2. Review.

PMID:
24504983
10.
11.

Switching from salmeterol/fluticasone to formoterol/budesonide combinations improves peripheral airway/alveolar inflammation in asthma.

Akamatsu T, Shirai T, Kato M, Yasui H, Hashimoto D, Fujisawa T, Tsuchiya T, Inui N, Suda T, Chida K.

Pulm Pharmacol Ther. 2014 Feb;27(1):52-6. doi: 10.1016/j.pupt.2013.04.001. Epub 2013 Apr 11.

PMID:
23583566
12.

Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma.

Beeh KM, Moroni-Zentgraf P, Ablinger O, Hollaenderova Z, Unseld A, Engel M, Korn S.

Respir Res. 2014 Jun 3;15:61. doi: 10.1186/1465-9921-15-61.

13.

Predictors of asthma control and lung function responsiveness to step 3 therapy in children with uncontrolled asthma.

Rabinovitch N, Mauger DT, Reisdorph N, Covar R, Malka J, Lemanske RF Jr, Morgan WJ, Guilbert TW, Zeiger RS, Bacharier LB, Szefler SJ.

J Allergy Clin Immunol. 2014 Feb;133(2):350-6. doi: 10.1016/j.jaci.2013.07.039. Epub 2013 Sep 29.

14.

Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD.

Briggs DD Jr, Covelli H, Lapidus R, Bhattycharya S, Kesten S, Cassino C.

Pulm Pharmacol Ther. 2005;18(6):397-404. Epub 2005 Apr 25.

PMID:
16179215
15.

Potential masking effects of salmeterol on airway inflammation in asthma.

Mcivor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR.

Am J Respir Crit Care Med. 1998 Sep;158(3):924-30.

PMID:
9731027
16.

Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.

D'Alonzo GE, Nathan RA, Henochowicz S, Morris RJ, Ratner P, Rennard SI.

JAMA. 1994 May 11;271(18):1412-6.

PMID:
7909853
17.

Acute effects of salmeterol and fluticasone propionate alone and in combination on airway blood flow in patients with asthma.

Mendes ES, Rebolledo P, Wanner A.

Chest. 2012 May;141(5):1184-9. doi: 10.1378/chest.11-0685. Epub 2011 Oct 6.

PMID:
21980058
18.

Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM, Rabe KF, Fabbri LM; POET-COPD Investigators.

N Engl J Med. 2011 Mar 24;364(12):1093-1103. doi: 10.1056/NEJMoa1008378.

19.

The therapeutic effects of inhaled long-acting beta2-adrenergics (LABA) and corticosteroids (ICS) are not affected by their inhalation sequence in moderate/persistent asthma.

Dal Negro RW, Micheletto C, Tognella S, Trevisan F, Guerriero M.

Eur Ann Allergy Clin Immunol. 2006 May;38(5):153-7.

PMID:
17058847
20.

Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids.

Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ.

Chest. 2001 Apr;119(4):1021-6.

PMID:
11296164
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk